ResultsIQ

ResultsIQ › Latest results › Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited Q2 FY27 earnings call summary

NSE: SOLARA · BSE: 541540

Earnings call of 16 Oct 2026, summarised by AI from the filing.

Down to ₹500-odd cr from ₹614-odd cr as on March 2026, helped by ₹100-odd cr of rights issue money.

Key takeaways

  1. Net debt Down to ₹500-odd cr from ₹614-odd cr as on March 2026, helped by ₹100-odd cr of rights issue money.
  2. Raw material West Asia crisis keeps raw material availability and pricing under pressure, with intermittent production stoppages.

Original filing on BSE

Solara Active Pharma Sciences Limited Q2 FY27 results

As filed: Revenue ₹417 cr (+33% year on year), EBITDA ₹76.8 cr (+120% year on year), PAT ₹28.5 cr, EBITDA margin 18.4% (+727 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹382 cr (+20% year on year), EBITDA ₹62.0 cr (+7% year on year), PAT ₹16.3 cr (+48% year on year), EBITDA margin 16.2% (−194 bps). Score 47 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it. EBITDA margin fell 194 bps year on year. Tax rate 0%. Share price after the results: +17.8% in 29 days (Nifty 500: +2.4%).
  • Q4 FY26: Revenue ₹387 cr (+42% year on year), EBITDA ₹57.7 cr (+28% year on year), PAT ₹9.6 cr, EBITDA margin 14.9% (−160 bps). Score 62 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 160 bps year on year. Other income 49% of PBT. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +4.9% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹349 cr (+16% year on year), EBITDA ₹37.3 cr (−37% year on year), PAT −₹17.4 cr (−234% year on year), EBITDA margin 10.7% (−897 bps). Score 20 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 897 bps year on year. Share price after the results: −12.8% in 28 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹314 cr (−10% year on year), EBITDA ₹35.0 cr (−43% year on year), PAT −₹10.0 cr (−225% year on year), EBITDA margin 11.2% (−643 bps). Score 20 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend. EBITDA margin fell 643 bps year on year. Profit fell 191% from last quarter. Share price after the results: −10.6% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹319 cr (−12% year on year), EBITDA ₹58.0 cr (+38% year on year), PAT ₹11.0 cr, EBITDA margin 18.2% (+661 bps). Score 42 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 661 bps year on year. Tax rate 0%. Share price after the results: −3.9% in 28 days (Nifty 500: −1.3%).
  • Q4 FY25: Revenue ₹273 cr (−9% year on year), EBITDA ₹45.0 cr (+300% year on year), PAT −₹2.0 cr, EBITDA margin 16.5% (+1,000 bps). Score 45 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was well above it. EBITDA margin rose 1000 bps year on year. Revenue fell 9% from last quarter. Share price after the results: −12.2% in 29 days (Nifty 500: +1.8%).
  • Q3 FY25: Revenue ₹300 cr (+20% year on year), EBITDA ₹59.0 cr, PAT ₹8.0 cr, EBITDA margin 19.7% (+1,000 bps). Score 73 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate 0%. Revenue fell 14% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Solara Active Pharma Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.